ARS Pharmaceuticals Appoints Donn Casale As New CEO

ARS Pharmaceuticals (NASDAQ:SPRY) announced that Richard Lowenthal, its co-founder and CEO, will step down effective July 6. Donn Casale, the company's current President with over 25 years of biopharma experience, has been appointed as the new CEO starting July 7.

By Muhammad Ali Khalid Wed, July 15, 2026 at 6:42 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 15:42 UTC

ARS Pharmaceuticals Appoints Donn Casale As New CEO

Tickers: $SPRY

Topics: biopharma CEO change executive leadership

Read the full article at Yahoo Finance

More World news

Marvell Technology Appoints Three Independent Directors Prior to Proposed Lumentum Acquisition Seeking Alpha · November 12, 2026, 14:35 UTC
M-tron Industries Reports Q3 2026 GAAP EPS Miss Amid Low Revenue Seeking Alpha · November 12, 2026, 14:37 UTC
Nexxen International Reports Q3 Earnings Beat with Revenue Growth and Increased EBITDA Seeking Alpha · November 12, 2026, 14:30 UTC
Brookfield Corporation Announces Quarterly Dividend of $0.07 Per Share Seeking Alpha · November 12, 2026, 14:30 UTC
Upwork Expands Restructuring Plan to Reduce Workforce by 37% Seeking Alpha · November 12, 2026, 14:34 UTC
Deswell Industries Reports First-Half Revenue of $33.02 Million Amid Segment Shifts Seeking Alpha · November 12, 2026, 14:35 UTC
Avicanna Reports Q3 Results with Positive Adjusted EBITDA and Reduced Operating Losses Seeking Alpha · November 12, 2026, 14:29 UTC
Bridgemarq Real Estate Services Announces Monthly Dividend of CAD 0.0125 per Share Seeking Alpha · November 12, 2026, 14:29 UTC
Natus Medical Expands Global Clinical Collaboration via New EMG and EEG Advisory Boards PR Newswire · November 12, 2026, 14:33 UTC
CoreWeave Reports Strong Third-Quarter Results Driven by AI Demand Motley Fool · November 12, 2026, 14:30 UTC